tetano
Editor, Senior Moderator
J Infect Chemother
. 2021 Mar 15;S1341-321X(21)00082-9.
doi: 10.1016/j.jiac.2021.03.008. Online ahead of print.
Evaluation of four commercial severe acute respiratory coronavirus 2 antibody tests
Nobuyuki Ashizawa[SUP] 1 [/SUP], Takahiro Takazono[SUP] 2 [/SUP], Kaname Ohyama[SUP] 3 [/SUP], Yoji Nagasaki[SUP] 4 [/SUP], Masaki Okamoto[SUP] 5 [/SUP], Tatsuro Hirayama[SUP] 1 [/SUP], Kensuke Takahashi[SUP] 6 [/SUP], Hirotomo Yamanashi[SUP] 7 [/SUP], Masato Tashiro[SUP] 8 [/SUP], Naoki Hosogaya[SUP] 9 [/SUP], Takeshi Tanaka[SUP] 10 [/SUP], Kazuko Yamamoto[SUP] 11 [/SUP], Yuichi Fukuda[SUP] 12 [/SUP], Yoshifumi Imamura[SUP] 1 [/SUP], Toshinori Kawanami[SUP] 13 [/SUP], Taiga Miyazaki[SUP] 14 [/SUP], Toyomitsu Sawai[SUP] 15 [/SUP], Kiyoyasu Fukushima[SUP] 16 [/SUP], Kazuhiro Yatera[SUP] 13 [/SUP], Katsunori Yanagihara[SUP] 17 [/SUP], Koichi Izumikawa[SUP] 8 [/SUP], Hiroshi Mukae[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: Numerous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological tests exists commercially; however, their performance using clinical samples is limited. Although insufficient to detect SARS-CoV-2 in the early phase of infection, antibody assays can be of great use for surveillance studies or for some coronavirus disease 2019 (COVID-19) patients presenting late to the hospital.
Methods: This study evaluated the sensitivity and specificity of four commercial SARS-CoV-2 lateral flow antibody tests using 213 serum specimens from 90 PCR-positive confirmed COVID-19 patients. Of 59 negative control sera, 50 were obtained from patients with other respiratory infectious diseases before COVID-19 pandemic began while nine were from patients infected with other respiratory viruses, including two seasonal coronaviruses.
Results: The varied sensitivities for the four commercial kits were 70.9%, 65.3%, 45.1%, and 65.7% for BioMedomics, Autobio Diagnostics, Genbody, and KURABO, respectively, between sick days 1 and 155 in COVID-19 patients. The sensitivities of the four tests gradually increased over time after infection before sick day 5 (15.0%, 12.5%, 15.0%, and 20.0%); from sick day 11-15 (95.7%, 87.2%, 53.2%, and 89.4%); and after sick day 20 (100%, 100%, 68.6%, and 96.1%), respectively. For severe illness, the sensitivities were quite high in the late phase after sick day 15. The specificities were over 96% for all four tests. No cross-reaction due to other pathogens, including seasonal coronaviruses, was observed.
Conclusions: Our results demonstrated the large differences in the antibody test performances. This ought to be considered when performing surveillance analysis.
Keywords: Antibody tests; COVID-19; IgG; IgM; SARS-CoV-2.
. 2021 Mar 15;S1341-321X(21)00082-9.
doi: 10.1016/j.jiac.2021.03.008. Online ahead of print.
Evaluation of four commercial severe acute respiratory coronavirus 2 antibody tests
Nobuyuki Ashizawa[SUP] 1 [/SUP], Takahiro Takazono[SUP] 2 [/SUP], Kaname Ohyama[SUP] 3 [/SUP], Yoji Nagasaki[SUP] 4 [/SUP], Masaki Okamoto[SUP] 5 [/SUP], Tatsuro Hirayama[SUP] 1 [/SUP], Kensuke Takahashi[SUP] 6 [/SUP], Hirotomo Yamanashi[SUP] 7 [/SUP], Masato Tashiro[SUP] 8 [/SUP], Naoki Hosogaya[SUP] 9 [/SUP], Takeshi Tanaka[SUP] 10 [/SUP], Kazuko Yamamoto[SUP] 11 [/SUP], Yuichi Fukuda[SUP] 12 [/SUP], Yoshifumi Imamura[SUP] 1 [/SUP], Toshinori Kawanami[SUP] 13 [/SUP], Taiga Miyazaki[SUP] 14 [/SUP], Toyomitsu Sawai[SUP] 15 [/SUP], Kiyoyasu Fukushima[SUP] 16 [/SUP], Kazuhiro Yatera[SUP] 13 [/SUP], Katsunori Yanagihara[SUP] 17 [/SUP], Koichi Izumikawa[SUP] 8 [/SUP], Hiroshi Mukae[SUP] 1 [/SUP]
Affiliations
- PMID: 33781691
- DOI: 10.1016/j.jiac.2021.03.008
Abstract
Introduction: Numerous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological tests exists commercially; however, their performance using clinical samples is limited. Although insufficient to detect SARS-CoV-2 in the early phase of infection, antibody assays can be of great use for surveillance studies or for some coronavirus disease 2019 (COVID-19) patients presenting late to the hospital.
Methods: This study evaluated the sensitivity and specificity of four commercial SARS-CoV-2 lateral flow antibody tests using 213 serum specimens from 90 PCR-positive confirmed COVID-19 patients. Of 59 negative control sera, 50 were obtained from patients with other respiratory infectious diseases before COVID-19 pandemic began while nine were from patients infected with other respiratory viruses, including two seasonal coronaviruses.
Results: The varied sensitivities for the four commercial kits were 70.9%, 65.3%, 45.1%, and 65.7% for BioMedomics, Autobio Diagnostics, Genbody, and KURABO, respectively, between sick days 1 and 155 in COVID-19 patients. The sensitivities of the four tests gradually increased over time after infection before sick day 5 (15.0%, 12.5%, 15.0%, and 20.0%); from sick day 11-15 (95.7%, 87.2%, 53.2%, and 89.4%); and after sick day 20 (100%, 100%, 68.6%, and 96.1%), respectively. For severe illness, the sensitivities were quite high in the late phase after sick day 15. The specificities were over 96% for all four tests. No cross-reaction due to other pathogens, including seasonal coronaviruses, was observed.
Conclusions: Our results demonstrated the large differences in the antibody test performances. This ought to be considered when performing surveillance analysis.
Keywords: Antibody tests; COVID-19; IgG; IgM; SARS-CoV-2.